ArticleDrug delivery2023
Phytic acid-modified manganese dioxide nanoparticles oligomer for magnetic resonance imaging and targeting therapy of osteosarcoma.
Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Manganese-derived biomaterials for tumor diagnosis and therapy.Journal of nanobiotechnology · 2024Pooled it
- Multifunctional nanoplatforms deciphering immune resistance in bone tumors: cooperative delivery, immune reprogramming and microenvironment remodeling.Journal of nanobiotechnology · 2026Review
- Material-Driven Therapeutics: Functional Nanomaterial Design Paradigms Revolutionizing Osteosarcoma Treatment.Journal of functional biomaterials · 2025Review
- A Hydrothermal and Combustion-Reduction Process with Polyvinyl Pyrrolidone as a Restricted Growth Agent and Galactose as a Reducing Agent for the Fabrication of Rod-like α-FeMaterials (Basel, Switzerland) · 2025Article
- Nanoparticles and bone microenvironment: a comprehensive review for malignant bone tumor diagnosis and treatment.Molecular cancer · 2024Review
- Recent advances in nanoadjuvant-triggered STING activation for enhanced cancer immunotherapy.Heliyon · 2024Review
- Network pharmacology and experimental validation to study the potential mechanism of Tongguanteng injection in regulating apoptosis in osteosarcoma.BMC complementary medicine and therapies · 2024Article
- Progress of Nanomaterials Based on Manganese Dioxide in the Field of Tumor Diagnosis and Therapy.International journal of nanomedicine · 2024Review
- Engineered nanomaterials enhance drug delivery strategies for the treatment of osteosarcoma.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is the most common malignant tumor in the skeletal system with high mortality. Phytic acid (PA) is a natural compound extracted from plant seeds, which shows certain antitumor activity and good bone targeting ability. To develop a novel theranostics for magnetic resonance imaging (MRI) and targeting therapy of osteosarcoma, we employed PA to modify manganese dioxide nanoparticles (MnO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.